<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: December ", fill: "#ed1c24"},
{source: "1: December ", target: "1: posted net income", fill: "#ed1c24"},
{source: "1: December ", target: "5: spending will accelerate as", fill: "#f4bbff"},
{source: "5: spending will accelerate as", target: "5: increased clinical", fill: "#f4bbff"},
{source: "5: increased clinical", target: "5: trial costs", fill: "#f4bbff"},
{source: "5: trial costs", target: "5: expenses associated with regulatory approval", fill: "#f4bbff"},
{source: "5: expenses associated with regulatory approval", target: "5: commercialization", fill: "#f4bbff"},
{source: "5: commercialization", target: "5: development", fill: "#f4bbff"},
{source: "5: development", target: "5: products discovered", fill: "#f4bbff"},
{source: "5: spending will accelerate as", target: "8: will depend on", fill: "#dc143c"},
{source: "8: will depend on", target: "8: regulatory approvals", fill: "#dc143c"},
{source: "8: regulatory approvals", target: "8: development", fill: "#dc143c"},
{source: "8: development", target: "8: product launch costs", fill: "#dc143c"},
{source: "8: product launch costs", target: "8: PAGE ", fill: "#dc143c"},
{source: "8: PAGE ", target: "8: introduction", fill: "#dc143c"},
{source: "8: introduction", target: "8: market acceptance", fill: "#dc143c"},
{source: "8: market acceptance", target: "8: new products", fill: "#dc143c"},
{source: "8: new products", target: "8: competing companies", fill: "#dc143c"},
{source: "8: competing companies", target: "8: infrastructure", fill: "#dc143c"},
{source: "8: infrastructure", target: "8: geographic markets", fill: "#dc143c"},
{source: "8: geographic markets", target: "8: acquisition", fill: "#dc143c"},
{source: "8: acquisition", target: "8: jurisdictions", fill: "#dc143c"},
{source: "8: jurisdictions", target: "8: recognition", fill: "#dc143c"},
{source: "8: recognition", target: "8: certain research", fill: "#dc143c"},
{source: "8: certain research", target: "8: milestones", fill: "#dc143c"},
{source: "8: milestones", target: "8: license fees", fill: "#dc143c"},
{source: "8: will depend on", target: "14: products even", fill: "#9b111e"},
{source: "14: products even", target: "14: approved cannot", fill: "#9b111e"},
{source: "14: approved cannot", target: "14: successfully commercialized", fill: "#9b111e"},
{source: "14: successfully commercialized", target: "14: financial condition", fill: "#9b111e"},
{source: "14: financial condition", target: "14: operations", fill: "#9b111e"},
{source: "14: operations", target: "14: liquidity could", fill: "#9b111e"},
{source: "14: liquidity could", target: "14: materially adversely affected which could", fill: "#9b111e"},
{source: "14: materially adversely affected which could", target: "14: negative impact on", fill: "#9b111e"},
{source: "14: negative impact on", target: "14: common stock", fill: "#9b111e"},
{source: "14: common stock", target: "14: debt securities obligations", fill: "#9b111e"},
{source: "14: products even", target: "31: product liability", fill: "#71a6d2"},
{source: "31: product liability", target: "31: based on", fill: "#71a6d2"},
{source: "31: based on", target: "31: allegations", fill: "#71a6d2"},
{source: "31: allegations", target: "31: technology", fill: "#71a6d2"},
{source: "31: technology", target: "31: effects whether by participants", fill: "#71a6d2"},
{source: "31: effects whether by participants", target: "31: clinical trials by patients using", fill: "#71a6d2"},
{source: "31: clinical trials by patients using", target: "31: persons exposed", fill: "#71a6d2"},
{source: "31: product liability", target: "41: Celgene Cellular Therapeutics ", fill: "#7851a9"},
{source: "41: Celgene Cellular Therapeutics ", target: "41: subsidiary may represent", fill: "#7851a9"},
{source: "41: subsidiary may represent", target: "41: departures from established treatment methods", fill: "#7851a9"},
{source: "41: departures from established treatment methods", target: "41: will compete with", fill: "#7851a9"},
{source: "41: will compete with", target: "41: traditional drugs", fill: "#7851a9"},
{source: "41: traditional drugs", target: "41: therapies which", fill: "#7851a9"},
{source: "41: therapies which", target: "41: manufactured", fill: "#7851a9"},
{source: "41: manufactured", target: "41: marketed by major pharmaceutical", fill: "#7851a9"},
{source: "41: marketed by major pharmaceutical", target: "41: biopharmaceutical", fill: "#7851a9"},
{source: "41: Celgene Cellular Therapeutics ", target: "44: currently manufacture", fill: "#9b870c"},
{source: "44: currently manufacture", target: "44: commercial scale", fill: "#9b870c"},
{source: "44: commercial scale", target: "44: raw materials", fill: "#9b870c"},
{source: "44: currently manufacture", target: "45: Neuchatel Switzerland ", fill: "#fff8dc"},
{source: "45: Neuchatel Switzerland ", target: "45: constructing", fill: "#fff8dc"},
{source: "45: constructing", target: "45: manufacturing", fill: "#fff8dc"},
{source: "45: manufacturing", target: "45: facility", fill: "#fff8dc"},
{source: "45: facility", target: "45: manufacture", fill: "#fff8dc"},
{source: "45: manufacture", target: "45: necessary", fill: "#fff8dc"},
{source: "45: Neuchatel Switzerland ", target: "91: also provides", fill: "#ffd800"},
{source: "91: also provides", target: "91: inspection by", fill: "#ffd800"},
{source: "91: inspection by", target: "91: establishments", fill: "#ffd800"},
{source: "91: also provides", target: "97: patent positions", fill: "#b87333"},
{source: "97: patent positions", target: "97: pharmaceutical", fill: "#b87333"},
{source: "97: pharmaceutical", target: "97: biopharmaceutical firms", fill: "#b87333"},
{source: "97: biopharmaceutical firms", target: "97: involve complex legal", fill: "#b87333"},
{source: "97: patent positions", target: "START_HERE", fill: "#b87333"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Asset Management and Custody Banks</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
    <tr>
      <td>Pharmaceuticals Biotechnology and Life Sciences</td>
    </tr>
    <tr>
      <td>Pharmaceuticals</td>
    </tr>
    <tr>
      <td>Environmental Services</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Biotechnology</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Policy</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Intelligence</td>
    </tr>
    <tr>
      <td>Judicial</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Leadership</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Human illness</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Threaten</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Sanction</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Travel to meet</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Psychological state</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December">December</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_17">December 17</a></td>
      <td>December 17 is the 351st day of the year (352nd in leap years) in the Gregorian calendar;  14 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n497 BC – The first Saturnalia festival was celebrated in ancient Rome.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_10">December 10</a></td>
      <td>December 10 is the 344th day of the year (345th in leap years) in the Gregorian calendar;  21 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n1317 – The "Nyköping Banquet": King Birger of Sweden treacherously seizes his two brothers Valdemar, Duke of Finland and Eric, Duke of Södermanland, who were subsequently starved to death in the dungeon of Nyköping Castle.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1924_German_federal_election">December 1924 German federal election</a></td>
      <td>Federal elections were held in Germany on 7 December 1924, the second that year after the Reichstag had been dissolved on 20 October. The Social Democratic Party remained the largest party in the Reichstag, receiving an increased share of the vote and winning 131 of the 493 seats.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_1">December 1</a></td>
      <td>December is the twelfth and the final month of the year in the Julian and Gregorian calendars. It is also the last of seven months to have a length of 31 days.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2016_in_aviation">2016 in aviation</a></td>
      <td>This is a list of aviation-related events from 2016.\n\n\n== Events ==\n\n\n=== January ===\nThe Government of Italy permitted United States unmanned aerial vehicles (UAVs or drones) to fly strike missions from Naval Air Station Sigonella in Sicily where the US has operated unarmed surveillance UAVs since 2001 against Islamic State targets in Libya, but only if they are "defensive," protecting U.S. forces or rescuers retrieving downed pilots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_18">December 18</a></td>
      <td>December 11 is the 345th day of the year (346th in leap years) in the Gregorian calendar;  20 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n220 – Emperor Xian of Han is forced to abdicate the throne by Cao Cao's son Cao Pi, ending the Han dynasty.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_26">December 26</a></td>
      <td>December 15 is the 349th day of the year (350th in leap years) in the Gregorian calendar;  16 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n533 – Vandalic War: Byzantine general Belisarius defeats the Vandals, commanded by King Gelimer, at the Battle of Tricamarum.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_31">December 31</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/December_8">December 8</a></td>
      <td>December 3 is the 337th day of the year (338th in leap years) in the Gregorian calendar;  28 days remain until the end of the year.\n\n\n== Events ==\n\n\n=== Pre-1600 ===\n915 – Pope John X crowns Berengar I of Italy as Holy Roman Emperor (probable date).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Research_and_development">Research and development</a></td>
      <td>Research and development (R&amp;D or R+D), known in Europe as research and technological development (RTD), is the set of innovative activities undertaken by corporations or governments in developing new services or products, and improving existing ones. Research and development constitutes the first stage of development of a potential new service or the production process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sustainable_development">Sustainable development</a></td>
      <td>Sustainable development is an organizing principle for meeting human development goals while also sustaining the ability of natural systems to provide the natural resources and ecosystem services on which the economy and society depend. The desired result is a state of society where living conditions and resources are used to continue to meet human needs without undermining the integrity and stability of the natural system.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Arrested_Development">Arrested Development</a></td>
      <td>Arrested Development is an American television sitcom created by Mitchell Hurwitz, which originally aired on Fox for three seasons from  2003 to 2006, followed by a two-season revival on Netflix from 2013 to 2019. The show follows the Bluths, a formerly wealthy dysfunctional family.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Development/For!">Development/For!</a></td>
      <td>Development/For! (Latvian: Attīstībai/Par!, AP!) is a liberal political alliance in Latvia.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_development">Software development</a></td>
      <td>Software development is the process of conceiving, specifying, designing, programming, documenting, testing, and bug fixing involved in creating and maintaining applications, frameworks, or other software components. Software development involves writing and maintaining the source code, but in a broader sense, it includes all processes from the conception of the desired software through to the final manifestation of the software, typically in a planned and structured process.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Child_development">Child development</a></td>
      <td>Child development involves the biological, psychological and emotional changes that occur in human beings between birth and the conclusion of adolescence. Childhood is divided into 3 stages of life which include early childhood, middle childhood, late childhood ( preadolescence).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Prenatal_development">Prenatal development</a></td>
      <td>Prenatal development (from Latin  natalis 'relating to birth') includes the development of the embryo and of the foetus during a viviparous animal's gestation. Prenatal development starts with fertilization, in the germinal stage of embryonic development, and continues in fetal development until birth.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Class_B_share">Class B share</a></td>
      <td>In finance, a Class B share or Class C share is a designation for a share class of a common or preferred stock that typically has strengthened voting rights or other benefits compared to a Class A share that may have been created. The equity structure, or how many types of shares are offered, is determined by the corporate charter.B share can also refer to various terms relating to stock classes:\n\nB share (mainland China), a class of stock on the Shanghai and Shenzhen stock exchanges\nB share (NYSE), a class of stock on the New York Stock ExchangeMost of the time, Class B shares may have lower repayment priorities in the event a company declares bankruptcy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Technology">Technology</a></td>
      <td>Technology is the result of accumulated knowledge and application of skills, methods, and processes used in industrial production and scientific research. Technology is embedded in the operation of all machines, with or without detailed knowledge of their function, for the intended purpose of an organization.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Pharmaceutical_manufacturing">Pharmaceutical manufacturing</a></td>
      <td>Pharmaceutical manufacturing is the process of industrial-scale synthesis of pharmaceutical drugs as part of the pharmaceutical industry.  The process of drug manufacturing can be broken down into a series of unit operations, such as milling, granulation, coating, tablet pressing, and others.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Software_patent">Software patent</a></td>
      <td>A software patent is a patent on a piece of software, such as a computer program, libraries, user interface, or algorithm.\n\n\n== Background ==\nA patent is a set of exclusionary rights granted by a state to a patent holder for a limited period of time, usually 20 years.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>CELGENE CORP /DE/    ITEM 1A RISK FACTORS    ALTHOUGH WE ARE CURRENTLY PROFITABLE, WE HAVE A HISTORY OF OPERATING LOSSES AND  AN ACCUMULATED DEFICIT    For the years ended <font color="blue">December </font>31, 2005, 2004 and 2003, we <font color="blue">posted net income</font> of  dlra63dtta7 million, dlra52dtta8 million and dlra25dtta7 million, <font color="blue">respectively</font></td>
    </tr>
    <tr>
      <td>Prior to 2003, we  had sustained losses in each year since our <font color="blue">incorporation</font> in 1986</td>
    </tr>
    <tr>
      <td>In addition,  we had an <font color="blue">accumulated deficit</font> of dlra170dtta8 million at <font color="blue">December </font>31, 2005 compared  with dlra234dtta4 million at <font color="blue">December </font>31, 2004</td>
    </tr>
    <tr>
      <td>We expect to make substantial  <font color="blue"><font color="blue">expenditure</font>s</font> to further develop and <font color="blue">commercialize</font> our products</td>
    </tr>
    <tr>
      <td>We also expect  that our rate of <font color="blue">spending will accelerate as</font> the result of <font color="blue">increased clinical</font>  <font color="blue">trial costs</font> and <font color="blue">expenses <font color="blue">associated with</font> <font color="blue">regulatory</font> approval</font> and  <font color="blue">commercialization</font> of products now in <font color="blue">development</font> and <font color="blue">products discovered</font>,  licensed or acquired by us in the future</td>
    </tr>
    <tr>
      <td>WE MAY EXPERIENCE SIGNIFICANT FLUCTUATIONS IN OUR QUARTERLY OPERATING RESULTS    We have <font color="blue">historically</font> experienced, and expect to continue for the foreseeable  future to experience, <font color="blue"><font color="blue">significant</font> <font color="blue">fluctuations</font></font> in our quarterly operating  results</td>
    </tr>
    <tr>
      <td>These <font color="blue">fluctuations</font> are due to a number of factors, many of which are  outside our control, and may result in <font color="blue">volatility</font> of our stock price</td>
    </tr>
    <tr>
      <td>Future  operating results <font color="blue">will depend on</font> many factors, including:         o    demand for our products;         o    <font color="blue"><font color="blue">regulatory</font> approvals</font> for our products;         o    the timing and level of research and <font color="blue">development</font> and sales and            marketing, including <font color="blue">product launch costs</font>;                                           17  <PAGE>         o    the timing and level of <font color="blue">reimbursement</font> from third-party payors for our            products;         o    the timing of the <font color="blue">introduction</font> and <font color="blue">market <font color="blue">acceptance</font></font> of <font color="blue">new products</font>            by us or <font color="blue">competing companies</font>;         o    the <font color="blue">development</font> or expansion of business <font color="blue">infrastructure</font> in new            clinical and <font color="blue">geographic markets</font>;         o    the <font color="blue">acquisition</font> of <font color="blue">new products</font> and companies;         o    tax rates in the <font color="blue">jurisdictions</font> in which we operate;         o    the timing and <font color="blue">recognition</font> of <font color="blue">certain research</font> and <font color="blue">development</font>            <font color="blue">milestones</font> and <font color="blue">license fees</font>; and         o    our ability to control our costs</td>
    </tr>
    <tr>
      <td>IF WE ARE UNSUCCESSFUL IN DEVELOPING AND COMMERCIALIZING OUR PRODUCTS, OUR  BUSINESS, FINANCIAL CONDITION AND RESULTS OF OPERATIONS COULD BE MATERIALLY  ADVERSELY AFFECTED WHICH COULD HAVE A NEGATIVE IMPACT ON THE VALUE OF OUR  SECURITIES    Many of our products and processes are in the early or mid-stages of research  and <font color="blue">development</font> and will require the <font color="blue">commitment</font> of substantial financial  resources, extensive research, <font color="blue">development</font>, preclinical testing, clinical  trials, <font color="blue">manufacturing</font> scale-up and <font color="blue"><font color="blue">regulatory</font> approval prior</font> to being ready for  sale</td>
    </tr>
    <tr>
      <td>With the exception of REVLIMID(R), THALOMID(R), ALKERAN(R), FOCALIN(TM)  and FOCALIN XR(TM) (the extended release version), all of our other product  <font color="blue">candidates</font> will require further <font color="blue">development</font>, clinical testing and <font color="blue">regulatory</font>  approvals before initial commercial marketing <font color="blue">in the <font color="blue">United States</font> </font>and  <font color="blue">internationally</font></td>
    </tr>
    <tr>
      <td>Moreover, REVLIMID(R) requires <font color="blue">further preclinical</font> and clinical  <font color="blue">testing as</font> a condition of approval and all of our <font color="blue">commercially available</font>  <font color="blue">products will</font> require further <font color="blue">development</font>, clinical testing and <font color="blue">regulatory</font>  <font color="blue">approvals as</font> we <font color="blue">seek approvals</font> in <font color="blue">new <font color="blue">indications</font></font> and <font color="blue">geographic markets</font></td>
    </tr>
    <tr>
      <td>If it  becomes too expensive to sustain our present <font color="blue">commitment</font> of <font color="blue">resources on</font> a  long-term basis, we will be unable to <font color="blue">continue certain <font color="blue">necessary</font> research</font> and  <font color="blue">development</font> <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>Furthermore, we cannot be certain that our clinical  <font color="blue">testing will</font> render satisfactory results, or that we will receive required  <font color="blue"><font color="blue">regulatory</font> approvals</font> for our <font color="blue">new products</font> or <font color="blue">new <font color="blue">indications</font></font></td>
    </tr>
    <tr>
      <td>If any of our  products, even if developed and approved, cannot be successfully <font color="blue">commercialize</font>d,  our business, <font color="blue">financial condition</font>, results of <font color="blue">operations</font> and <font color="blue">liquidity could</font> be  <font color="blue">materially adversely affected which could</font> have a <font color="blue">negative impact on</font> the value of  our <font color="blue">common stock</font> or <font color="blue">debt <font color="blue">securities <font color="blue">obligation</font>s</font></font></td>
    </tr>
    <tr>
      <td>At our present and anticipated level of <font color="blue">operations</font>, we may not be able to  maintain <font color="blue"><font color="blue">profitability</font> without continued growth</font> in our revenues</td>
    </tr>
    <tr>
      <td>The growth of  our business during the <font color="blue">next several years will</font> be <font color="blue">largely dependent on</font> the  <font color="blue">commercial success</font> of REVLIMID(R) and our other products</td>
    </tr>
    <tr>
      <td>REVLIMID(R) was  <font color="blue">approved by</font> the FDA on <font color="blue">December </font>27, 2005 for the treatment of certain  <font color="blue">myelodysplastic syndromes</font>, or MDS, <font color="blue">associated with</font> a deletion 5q cytogenetic  <font color="blue">abnormality</font></td>
    </tr>
    <tr>
      <td>REVLIMID(R) will be <font color="blue">distributed through contracted pharmacies under</font>  the RevAssist(sm) program, which is a <font color="blue">proprietary</font> risk-<font color="blue">management</font> distribution  <font color="blue">program tailored specifically</font> to <font color="blue">help ensure</font> the safe use of REVLIMID(R)</td>
    </tr>
    <tr>
      <td>We do  not have long-term data on the use of the product and <font color="blue">cannot <font color="blue">predict whether</font></font>  REVLIMID(R) will gain widespread <font color="blue">acceptance</font>, which will mostly depend on the  <font color="blue">acceptance</font> of regulators, physicians, patients and other <font color="blue">key opinion leaders as</font>  a <font color="blue"><font color="blue">relatively</font> safe</font> and <font color="blue"><font color="blue">effective</font> drug</font> that has <font color="blue">certain <font color="blue">advantages</font> as compared</font> to  existing                                           18  <PAGE>    or future therapies</td>
    </tr>
    <tr>
      <td>In addition, some of our <font color="blue">products compete with one</font> another  <font color="blue">as therapies designed</font> to <font color="blue">treat cancer</font></td>
    </tr>
    <tr>
      <td>For example, <font color="blue">market <font color="blue">acceptance</font></font> of  REVLIMID(R) may result to the detriment of THALOMID(R) and ALKERAN(R)</td>
    </tr>
    <tr>
      <td>We are  <font color="blue">also seeking</font> to market REVLIMID(R) in Europe as well as for other <font color="blue">indications</font> in  the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>A delay in gaining the requisite <font color="blue"><font color="blue">regulatory</font> approvals</font> could  <font color="blue">negatively impact</font> our growth plans and the value of our <font color="blue">common stock</font> or debt  <font color="blue">securities <font color="blue">obligation</font>s</font></td>
    </tr>
    <tr>
      <td>THALOMID(R) is <font color="blue">currently approved as</font> a therapy for the treatment of ENL  However, the market for the use of THALOMID(R) in patients suffering from ENL is  <font color="blue">relatively</font> small and we are <font color="blue">dependent on revenues generated from</font> its off-label  use in <font color="blue">treating multiple myeloma</font> and other forms of cancer</td>
    </tr>
    <tr>
      <td>If THALOMID(R) does not receive market  approval, its off-label use in <font color="blue">treating multiple myeloma</font> and other forms of  <font color="blue">cancer may diminish over</font> time</td>
    </tr>
    <tr>
      <td>In addition, if adverse experiences are reported  in <font color="blue"><font color="blue">connection</font> with</font> the use of THALOMID(R) <font color="blue">by patients</font>, this <font color="blue">could undermine</font>  physician and <font color="blue">patient comfort with</font> the product, could limit the commercial  success of the product and <font color="blue">could even impact</font> the <font color="blue">acceptance</font> of our other  products, including REVLIMID(R)</td>
    </tr>
    <tr>
      <td>Also, we are <font color="blue">dependent upon sales</font> of  ALKERAN(R), which we <font color="blue">license from</font> GSK, and royalties <font color="blue">based on</font> Novartis &amp;apos  sales of  FOCALIN XR(TM), which we <font color="blue">cannot directly impact</font></td>
    </tr>
    <tr>
      <td>Our revenues and <font color="blue">profits would</font> be <font color="blue">negatively impact</font>ed if <font color="blue"><font color="blue">generic version</font>s</font> of any  of these products were to be approved and launched</td>
    </tr>
    <tr>
      <td>WE FACE THE RISK OF PRODUCT LIABILITY CLAIMS    We may be subject to a variety of <font color="blue">product liability</font> or other claims <font color="blue">based on</font>  <font color="blue"><font color="blue">allegation</font>s</font> that the use of our <font color="blue">technology</font> or products has resulted in adverse  effects, whether by participants in our <font color="blue">clinical trials</font>, <font color="blue">by patients</font> using our  products or by other <font color="blue">persons exposed</font> to our products</td>
    </tr>
    <tr>
      <td>Thalidomide, when used by  <font color="blue">pregnant women</font>, has resulted in <font color="blue">serious birth defects</font></td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">necessary</font> and  <font color="blue">strict precautions must</font> be <font color="blue">taken by physicians prescribing</font> the drug and  <font color="blue">pharmacies dispensing</font> the drug to <font color="blue">women with childbearing potential</font></td>
    </tr>
    <tr>
      <td>These  <font color="blue">precautions may</font> not be observed in all cases or, if observed, may not be  <font color="blue">effective</font></td>
    </tr>
    <tr>
      <td>Use of thalidomide has also been associated, in a limited number of  cases, with other side effects, including nerve damage</td>
    </tr>
    <tr>
      <td>Although we have product  <font color="blue">liability insurance</font> that we believe is sufficient, we may be unable to maintain  <font color="blue">existing coverage</font> or obtain <font color="blue">additional coverage on commercially reasonable terms</font>  if required, or our <font color="blue">coverage may</font> be inadequate to <font color="blue">protect us</font> in the event of a  multitude of claims being asserted <font color="blue">against us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">obligation</font> to <font color="blue">defend against</font>  or pay any <font color="blue">product liability</font> or other claim may be expensive and divert the  efforts of our <font color="blue">management</font> and <font color="blue">technical personnel</font></td>
    </tr>
    <tr>
      <td>IF OUR PRODUCTS ARE NOT ACCEPTED BY THE MARKET, DEMAND FOR OUR PRODUCTS WILL  DETERIORATE OR NOT MATERIALIZE AT ALL    It is <font color="blue">necessary</font> that our and our distribution partners &amp;apos  products, including  REVLIMID(R), THALOMID(R), ALKERAN(R), FOCALIN(TM) and FOCALIN XR(TM), and the  RITALIN(R) family of drugs achieve and maintain <font color="blue">market <font color="blue">acceptance</font></font></td>
    </tr>
    <tr>
      <td>A number of  factors can render the degree of <font color="blue">market <font color="blue">acceptance</font></font> of our <font color="blue">products uncertain</font>,  including the products &amp;apos  efficacy, safety and <font color="blue">advantages</font>, if any, <font color="blue">over competing</font>  products, as well as the <font color="blue"><font color="blue">reimbursement</font> policies</font> of third-party payors, such as  <font color="blue">government</font> and <font color="blue">private insurance</font> plans</td>
    </tr>
    <tr>
      <td>In particular, thalidomide, when used by  <font color="blue">pregnant women</font>, has resulted in <font color="blue">serious birth defects</font>, and the <font color="blue">negative history</font>  <font color="blue">associated with</font> thalidomide and <font color="blue">birth defects may decrease</font> the <font color="blue">market <font color="blue">acceptance</font></font>  of THALOMID(R)</td>
    </tr>
    <tr>
      <td>In addition, the products that we are attempting to develop  through our <font color="blue">Celgene Cellular Therapeutics </font><font color="blue">subsidiary may represent</font> substantial  <font color="blue">departures from established treatment methods</font> and <font color="blue">will compete with</font> a number of  <font color="blue">traditional drugs</font> and <font color="blue">therapies which</font> are now, or may be in the future,  <font color="blue"><font color="blue">manufacture</font>d</font> and <font color="blue">marketed by major <font color="blue">pharmaceutical</font></font> and <font color="blue">bio<font color="blue">pharmaceutical</font></font>  companies</td>
    </tr>
    <tr>
      <td>Furthermore, public attitudes may be <font color="blue">influenced by</font> claims that stem  <font color="blue">cell therapy</font> is unsafe, and stem <font color="blue">cell therapy</font> may not gain the <font color="blue">acceptance</font> of the  public                                           19  <PAGE>    or the <font color="blue">medical community</font></td>
    </tr>
    <tr>
      <td>If our products are not <font color="blue">accepted by</font> the market, demand  for our <font color="blue">products will</font> deteriorate or not <font color="blue">materialize at</font> all</td>
    </tr>
    <tr>
      <td>WE HAVE NO COMMERCIAL MANUFACTURING FACILITIES AND IF THE THIRD-PARTY  MANUFACTURERS UPON WHOM WE RELY FAIL TO PRODUCE ON A TIMELY BASIS THE RAW  MATERIALS OR FINISHED PRODUCTS IN THE VOLUMES THAT WE REQUIRE OR FAIL TO MEET  QUALITY STANDARDS AND MAINTAIN NECESSARY LICENSURE FROM REGULATORY AUTHORITIES,  WE MAY BE UNABLE TO MEET DEMAND FOR OUR PRODUCTS, POTENTIALLY RESULTING IN LOST  REVENUES    We do not <font color="blue">currently <font color="blue">manufacture</font></font> any of our <font color="blue">products on</font> a <font color="blue">commercial scale</font> and  have <font color="blue">contracted with</font> third-party <font color="blue">manufacture</font>rs to supply the <font color="blue">raw materials</font> and  finished products to meet our needs</td>
    </tr>
    <tr>
      <td>Although a site has been purchased in  Neuchatel, Switzerland, and we are <font color="blue">constructing</font> a drug product <font color="blue">manufacturing</font>  <font color="blue">facility</font>, we cannot utilize this <font color="blue">facility</font> to <font color="blue">manufacture</font> our <font color="blue">marketed products</font>  until we obtain <font color="blue">necessary</font> FDA clearance</td>
    </tr>
    <tr>
      <td>Additionally, we intend to continue to  utilize outside <font color="blue">manufacture</font>rs as needed to produce certain of our <font color="blue">products on</font> a  <font color="blue">commercial scale</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">active <font color="blue">pharmaceutical</font></font> ingredient, or API, for THALOMID(R) is <font color="blue"><font color="blue">manufacture</font>d</font> by  Eagle Picher Pharmaceutical Services, a Division of Eagle-Picher Incorporated,  which has filed to <font color="blue">reorganize under</font> Chapter 11 of the <font color="blue">Bankruptcy Code</font></td>
    </tr>
    <tr>
      <td>We  currently have <font color="blue">adequate supplies</font> of API for THALOMID(R) on hand to support our  projected long-term <font color="blue"><font color="blue">requirement</font>s</font> and do not believe that the Eagle-Picher  Chapter 11 bankruptcy filing will result in any <font color="blue">supply disruptions</font> for the  <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>In addition, a <font color="blue">second supplier</font> is currently being qualified</td>
    </tr>
    <tr>
      <td>We rely on two drug product <font color="blue">manufacture</font>rs, Penn Pharmaceuticals Services Limited  and Institute of Drug Technology Australia Limited for the formulation and  <font color="blue">encapsulation</font> of the finished dosage form of THALOMID(R) capsules, and on one  <font color="blue">contract packager</font>, Sharp Corporation, for the packaging of the <font color="blue">final product</font></td>
    </tr>
    <tr>
      <td>The API for FOCALIN(TM) is currently obtained <font color="blue">from two suppliers</font>, Johnson  Matthey Inc</td>
    </tr>
    <tr>
      <td>and Seigfried USA, Inc, and we rely on a single <font color="blue">manufacture</font>r,  Mikart, Inc, for the tableting and packaging of FOCALIN(TM) finished product</td>
    </tr>
    <tr>
      <td>We obtain the API for FOCALIN XR(TM) from Johnson Matthey Inc, on behalf of  Novartis for the <font color="blue">manufacture</font> of FOCALIN XR(TM) finished product</td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> an <font color="blue"><font color="blue">agreement</font> with</font> <font color="blue">Evotec OAI Limited </font>for the supply of  REVLIMID(R) API, and have <font color="blue">contracted with</font> OSG Norwich Pharmaceuticals and Penn  Pharmaceuticals Services Limited for the <font color="blue">manufacture</font> of REVLIMID(R) finished  product</td>
    </tr>
    <tr>
      <td>In all the countries where we sell our products, <font color="blue">government</font>al <font color="blue">regulations</font> exist  to <font color="blue">define standards</font> for <font color="blue">manufacturing</font>, packaging and labeling and storing</td>
    </tr>
    <tr>
      <td>All  of our suppliers of <font color="blue">raw materials</font> and contract <font color="blue">manufacture</font>rs must <font color="blue">comply with</font>  these <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td>Failure to do so could result in supply <font color="blue">interruptions</font></td>
    </tr>
    <tr>
      <td>In the  <font color="blue">United States</font>, the FDA requires that all suppliers of <font color="blue"><font color="blue">pharmaceutical</font> bulk</font>  material and all <font color="blue">manufacture</font>rs of <font color="blue"><font color="blue">pharmaceutical</font>s</font> for sale in or from the United  States achieve and maintain <font color="blue">compliance with</font> the FDAapstas current Good Manufacturing  Practices (cGMP) <font color="blue">regulations</font> and <font color="blue">guidelines</font></td>
    </tr>
    <tr>
      <td>Failure of our third-party  <font color="blue">manufacture</font>rs to <font color="blue">comply with</font> applicable <font color="blue">regulations</font> could result in sanctions  being imposed on them or us, including fines, <font color="blue">injunctions</font>, civil penalties,  <font color="blue">disgorgement</font>, suspension or withdrawal of approvals, license revocation,  seizures or recalls of products, operating <font color="blue">restrictions</font> and criminal  <font color="blue"><font color="blue">prosecution</font>s</font>, any of <font color="blue">which could <font color="blue">significant</font>ly</font> and <font color="blue">adversely affect supplies</font> of  our products</td>
    </tr>
    <tr>
      <td>In addition, before any <font color="blue">product batch</font> produced by our  <font color="blue">manufacture</font>rs can be shipped, it <font color="blue">must conform</font> to <font color="blue">release specifications</font>  pre-<font color="blue">approved by</font> regulators for the content of the <font color="blue"><font color="blue">pharmaceutical</font> product</font></td>
    </tr>
    <tr>
      <td>If the  <font color="blue">operations</font> of one or more of our <font color="blue">manufacture</font>rs were to become unavailable for  any reason, any required FDA review and approval of the <font color="blue">operations</font> of an  <font color="blue"><font color="blue">alternative</font> supplier could</font> cause a delay in the <font color="blue">manufacture</font> of our products</td>
    </tr>
    <tr>
      <td>If  our outside <font color="blue">manufacture</font>rs do not meet our <font color="blue"><font color="blue">requirement</font>s</font> for quality, quantity or  <font color="blue">timeliness</font>, or do not achieve and maintain <font color="blue">compliance with</font> all applicable  <font color="blue">regulations</font>, demand for our products or our ability to <font color="blue">continue supplying such</font>  <font color="blue">products could substantially decline</font></td>
    </tr>
    <tr>
      <td>20  <PAGE>    WE HAVE LIMITED MARKETING AND DISTRIBUTION CAPABILITIES    Although we have a 234-person (including CCT) US <font color="blue"><font color="blue">pharmaceutical</font> commercial</font>  organization to support our products, we may be required to seek one or more  <font color="blue">corporate partners</font> to <font color="blue">provide marketing services with respect</font> to certain of our  products</td>
    </tr>
    <tr>
      <td>Any delay in securing these <font color="blue">resources could substantially delay</font> or  curtail the marketing of these products</td>
    </tr>
    <tr>
      <td>We have <font color="blue">contracted with</font> Ivers Lee  Corporation, d/b/a Sharp, a specialty <font color="blue">distributor</font>, to distribute THALOMID(R) and  REVLIMID(R)</td>
    </tr>
    <tr>
      <td>If Sharp does not perform its <font color="blue">obligation</font>s, our ability to  distribute THALOMID(R) and REVLIMID(R) may be <font color="blue">severely restricted</font></td>
    </tr>
    <tr>
      <td>WE RECEIVE SIGNIFICANT REVENUES FROM COLLABORATIONS AND MAY BE DEPENDENT ON  COLLABORATIONS AND LICENSES WITH THIRD PARTIES    Our ability to fully <font color="blue">commercialize</font> our preclinical and clinical-stage pipeline,  if developed, may depend to some <font color="blue">extent upon</font> our <font color="blue">entering into <font color="blue">collaborations</font></font>  with other <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">pharmaceutical</font></font> companies with the requisite  experience and financial and other resources to obtain <font color="blue"><font color="blue">regulatory</font> approvals</font> and  to <font color="blue">manufacture</font> and <font color="blue">market such products</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">collaborations</font> and licenses include  an exclusive license (excluding Canada) to Novartis for the <font color="blue">development</font> and  <font color="blue">commercialization</font> of FOCALIN(TM) and FOCALIN XR(TM); an <font color="blue"><font color="blue">agreement</font> with</font> Pharmion  Corporation to expand the THALOMID(R) franchise <font color="blue">internationally</font>; and an  <font color="blue"><font color="blue">agreement</font> with</font> GSK <font color="blue">enabling us</font> to distribute, promote and sell ALKERAN(R)</td>
    </tr>
    <tr>
      <td>Our  present and <font color="blue">future <font color="blue">arrangements</font> may</font> be <font color="blue">jeopardized</font> if any or all of the  following occur:         o    we are not able to <font color="blue">enter into additional <font color="blue">joint ventures</font></font> or other            <font color="blue">arrangements</font> on acceptable terms, if at all;         o    our <font color="blue">joint ventures</font> or other <font color="blue">arrangements</font> do not result in a compatible            working <font color="blue">relationship</font>;         o    our partners change their business priorities, fail to perform as            <font color="blue">agreed upon</font> or experience <font color="blue">financial difficulties</font> that disrupt            <font color="blue">necessary</font> business <font color="blue">operations</font>;         o    our <font color="blue">joint ventures</font> or other <font color="blue">arrangements</font> do not lead to the successful            <font color="blue">development</font> and <font color="blue">commercialization</font> of any products;         o    we are unable to obtain or maintain <font color="blue">proprietary</font> rights or licenses to            <font color="blue">technology</font> or products developed in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">joint ventures</font>            or other <font color="blue">arrangements</font>; or         o    we are unable to preserve the <font color="blue">confidentiality</font> of any <font color="blue">proprietary</font>            rights or information developed in <font color="blue"><font color="blue">connection</font> with</font> our <font color="blue">joint ventures</font>            or other <font color="blue">arrangements</font></td>
    </tr>
    <tr>
      <td>WE MAY CONTINUE TO MAKE STRATEGIC ACQUISITIONS OF OTHER COMPANIES BUSINESSES OR  PRODUCTS AND THESE ACQUISITIONS INTRODUCE SIGNIFICANT RISKS AND UNCERTAINTIES,  INCLUDING RISKS RELATED TO INTEGRATING THE ACQUIRED BUSINESSES AND PRODUCTS AND  TO ACHIEVING BENEFITS FROM THE ACQUISITIONS    To take advantage of <font color="blue">external growth opportunities</font>, we have made, and may  continue to make, strategic <font color="blue">acquisition</font>s that <font color="blue">involve <font color="blue">significant</font> risks</font> and  <font color="blue">uncertainties</font></td>
    </tr>
    <tr>
      <td>These risks and <font color="blue">uncertainties</font> include: (1) the <font color="blue">difficulty</font> in  integrating newly-acquired <font color="blue">businesses</font> and <font color="blue">operations</font> in an <font color="blue">efficient</font> and  <font color="blue">effective</font> manner; (2) the <font color="blue">challenges</font> in achieving strategic objectives, cost  savings and other benefits from <font color="blue">acquisition</font>s; (3) the risk that the <font color="blue">technologies</font>  acquired do not evolve as anticipated; (4) contracts, <font color="blue"><font color="blue">agreement</font>s</font>, assets and  <font color="blue">liabilities</font> are not as represented; (5) the <font color="blue">potential loss</font> of <font color="blue">key employees</font> of  the acquired <font color="blue">businesses</font>; (6) the risk of diverting the attention of senior  <font color="blue">management</font> from our other <font color="blue">operations</font>; (7) the risks of                                           21  <PAGE>    <font color="blue">entering new markets</font> in which we have limited experience; (8) difficulties in  expanding information <font color="blue">technology</font> systems and other business processes to  <font color="blue">accommodate</font> the acquired <font color="blue">businesses</font>; (9) future impairments of goodwill and  other <font color="blue">intangibles</font> of an acquired business; and, (10) the impact that possible  in-process research and <font color="blue">development</font> charges may have <font color="blue">on future earnings</font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">acquisition</font> <font color="blue">candidates</font> in the <font color="blue">bio<font color="blue">pharmaceutical</font></font>s industry carry high price  to <font color="blue">earnings valuations</font></td>
    </tr>
    <tr>
      <td>As a result, acquiring a business that has a high  valuation may be dilutive to our earnings, <font color="blue">especially</font> when the acquired business  has little or no revenue</td>
    </tr>
    <tr>
      <td>Key employees of acquired <font color="blue"><font color="blue">businesses</font> may</font> receive substantial value in <font color="blue">connection</font>  with a <font color="blue">transaction</font> in the form of change-in-control <font color="blue"><font color="blue">agreement</font>s</font>, acceleration of  <font color="blue">stock options</font> and the lifting of <font color="blue">restrictions</font> on other equity-based <font color="blue">compensation</font>  rights</td>
    </tr>
    <tr>
      <td>To retain <font color="blue">such employees</font> and integrate the acquired business, we may  offer additional, sometimes costly, retention incentives</td>
    </tr>
    <tr>
      <td>THE HAZARDOUS MATERIALS WE USE IN OUR RESEARCH, DEVELOPMENT AND OTHER BUSINESS  OPERATIONS COULD RESULT IN SIGNIFICANT LIABILITIES WHICH COULD EXCEED OUR  INSURANCE COVERAGE AND FINANCIAL RESOURCES    We <font color="blue">use certain hazardous materials</font> in our research, <font color="blue">development</font> and general  business <font color="blue">activities</font></td>
    </tr>
    <tr>
      <td>While we believe we are currently in substantial compliance  with the federal, state and <font color="blue">local laws</font> and <font color="blue">regulations</font> governing the use of  these materials, we cannot be certain that <font color="blue">accidental injury</font> or <font color="blue">contamination</font>  will not occur</td>
    </tr>
    <tr>
      <td>Any <font color="blue">such accident</font> or <font color="blue">contamination</font> could result in substantial  <font color="blue">liabilities</font> that <font color="blue">could exceed</font> our <font color="blue">insurance coverage</font> and <font color="blue">financial resources</font></td>
    </tr>
    <tr>
      <td>Additionally, the cost of <font color="blue">compliance with</font> <font color="blue">environmental</font> and safety laws and  <font color="blue">regulations</font> may increase in the future, requiring us to expend more financial  <font color="blue">resources either</font> in compliance or in purchasing supplemental <font color="blue">insurance coverage</font></td>
    </tr>
    <tr>
      <td>THE PHARMACEUTICAL INDUSTRY IS SUBJECT TO EXTENSIVE GOVERNMENT REGULATION WHICH  PRESENTS NUMEROUS RISKS TO US    The <font color="blue">discovery</font>, preclinical <font color="blue">development</font>, <font color="blue">clinical trials</font>, <font color="blue">manufacturing</font>,  marketing and labeling of <font color="blue"><font color="blue">pharmaceutical</font>s</font> and biologics are all subject to  extensive regulation by numerous <font color="blue">government</font>al <font color="blue">authorities</font> and agencies in the  <font color="blue">United States</font> and other countries</td>
    </tr>
    <tr>
      <td>If we or our <font color="blue">contractors</font> and <font color="blue">collaborators</font>  are delayed in receiving, or are unable to obtain at all, <font color="blue">necessary</font> <font color="blue">government</font>al  approvals, we will be unable to <font color="blue">effective</font>ly market our products</td>
    </tr>
    <tr>
      <td>The testing, marketing and <font color="blue">manufacturing</font> of our products require <font color="blue">regulatory</font>  approval, including <font color="blue">approval from</font> the FDA and, in some cases, from the US  Environmental Protection Agency, or the EPA, or <font color="blue">government</font>al <font color="blue">authorities</font> outside  of the <font color="blue">United States</font> that perform roles similar to those of the FDA and EPA  Certain of our <font color="blue"><font color="blue">pharmaceutical</font> product</font>s, such as FOCALIN(TM), <font color="blue">fall under</font> the  <font color="blue">Controlled Substances Act </font>of 1970 that requires <font color="blue">authorization</font> by the US Drug  Enforcement Agency, or DEA, of the US Department of Justice in order to handle  and distribute these products</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> approval process presents several  risks to us:         o    In general, preclinical tests and <font color="blue">clinical trials</font> can take many years,            and require the <font color="blue">expenditure</font> of substantial resources, and the data            obtained from these tests and trials can be susceptible to varying            <font color="blue">interpretation</font> that could delay, limit or prevent <font color="blue">regulatory</font> approval;         o    Delays or <font color="blue">rejections</font> may be <font color="blue">encountered</font> during any stage of the            <font color="blue">regulatory</font> process based upon the failure of the clinical or other            data to <font color="blue">demonstrate</font> <font color="blue">compliance with</font>, or upon the failure of the            product to meet, a <font color="blue">regulatory</font> agencyapstas <font color="blue"><font color="blue">requirement</font>s</font> for safety,            efficacy and quality or, in the case of a <font color="blue">product seeking</font> an orphan            drug indication, because another designee received <font color="blue">approval first</font>;                                           22  <PAGE>         o    <font color="blue">Requirements </font>for approval may become more stringent due to changes in            <font color="blue">regulatory</font> agency policy, or the adoption of new <font color="blue">regulations</font> or            <font color="blue">legislation</font>;         o    The scope of any <font color="blue">regulatory</font> approval, when obtained, <font color="blue">may <font color="blue">significant</font>ly</font>            limit the <font color="blue">indicated uses</font> for which a <font color="blue">product may</font> be marketed and            reimbursed and <font color="blue">may impose <font color="blue">significant</font> limitations</font> in the nature of            warnings, precautions and contra-<font color="blue">indications</font> that <font color="blue">could materially</font>            affect the sales and <font color="blue">profitability</font> of the drug;         o    Pricing and <font color="blue">reimbursement</font> controls;         o    Approved drugs, as well as their <font color="blue">manufacture</font>rs, are subject to            continuing and <font color="blue">ongoing review</font>, and <font color="blue">discovery</font> of <font color="blue">previously unknown</font>            <font color="blue">problems with</font> these products or the failure to adhere to <font color="blue">manufacturing</font>            or quality control <font color="blue"><font color="blue">requirement</font>s</font> may result in <font color="blue">restrictions</font> on their            <font color="blue">manufacture</font>, sale or use or in their <font color="blue">withdrawal from</font> the market;         o    <font color="blue">Regulatory </font><font color="blue">authorities</font> and <font color="blue">agencies may promulgate additional</font>            <font color="blue">regulations</font> restricting the sale of our existing and proposed            products;         o    Once a product receives <font color="blue">marketing approval</font>, we may not market that            product for broader or <font color="blue">different</font> <font color="blue"><font color="blue">application</font>s</font>, <font color="blue">and the FDA </font>may not            <font color="blue">grant us approval with respect</font> to separate product <font color="blue"><font color="blue">application</font>s</font> that            <font color="blue">represent extensions</font> of our basic <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>In addition, the FDA may            withdraw or <font color="blue">modify existing approvals</font> in a <font color="blue"><font color="blue">significant</font> manner</font> or            promulgate additional <font color="blue">regulations</font> restricting the sale of our present            or <font color="blue">proposed products</font>;         o    Products, such as REVLIMID(R), that are subject to <font color="blue">accelerated</font>            approval can be subject to an <font color="blue">expedited withdrawal</font> if the            post-marketing study <font color="blue">commitment</font>s are not completed <font color="blue">with due diligence</font>,            the post-marketing <font color="blue">restrictions</font> are not adhered to or are shown to be            inadequate to assure the safe use of the drug, or evidence            <font color="blue"><font color="blue">demonstrate</font>s</font> that the drug is not shown to be safe and <font color="blue">effective</font> under            its <font color="blue">conditions</font> of use</td>
    </tr>
    <tr>
      <td>Additionally, <font color="blue">promotional materials</font> for such            drugs are subject to <font color="blue">enhanced surveillance</font>, including pre-approval            review of all <font color="blue">promotional materials</font> used within 120 days following            <font color="blue">marketing approval</font> and a <font color="blue">requirement</font> for the submissions 30 days prior            to <font color="blue">initial dissemination</font> of all <font color="blue">promotional materials</font> disseminated            after 120 days following <font color="blue">marketing approval</font></td>
    </tr>
    <tr>
      <td>o    Our labeling and promotional <font color="blue">activities</font> relating to our products are            <font color="blue">regulated by</font> the FDA and state <font color="blue">regulatory</font> agencies and, in some            circumstances, by the DEA, and are subject to associated risks</td>
    </tr>
    <tr>
      <td>If we            fail to <font color="blue">comply with</font> FDA <font color="blue">regulations</font> prohibiting promotion of off-label            uses and the promotion of products for <font color="blue">which marketing clearance</font> has            not been obtained, the FDA, or the Office of the Inspector General of            <font color="blue">the Department of Health and Human Services </font>or the state Attorneys            General could bring an enforcement action <font color="blue">against us</font> that could            inhibit our <font color="blue">marketing capabilities as well as</font> result in <font color="blue">significant</font>            penalties</td>
    </tr>
    <tr>
      <td>The FDAapstas Center for Biologics Evaluation and Research <font color="blue">currently regulates under</font>  21 CFR Parts 1270 and 1271 human tissue intended for <font color="blue">transplantation</font> that is  recovered, processed, stored or <font color="blue">distributed by methods</font> that do not change tissue  function or <font color="blue">characteristics</font> and that is not <font color="blue">currently regulated as</font> a <font color="blue">human drug</font>,  <font color="blue">biological product</font> or medical device</td>
    </tr>
    <tr>
      <td>Certain stem cell <font color="blue">activities</font> fall within  this category</td>
    </tr>
    <tr>
      <td>Part 1270 requires <font color="blue">tissue <font color="blue">establishments</font></font> to screen and test  donors, to prepare and <font color="blue">follow written procedures</font> for the prevention of the  spread of <font color="blue">communicable disease</font> and to maintain records</td>
    </tr>
    <tr>
      <td>It <font color="blue">also provides</font> for  <font color="blue">inspection by</font> the FDA of <font color="blue">tissue <font color="blue">establishments</font></font></td>
    </tr>
    <tr>
      <td>Part 1271 requires <font color="blue">human cells</font>,  tissue and                                           23  <PAGE>    cellular and tissue-based product <font color="blue">establishments</font> (HCT/Ps) to register with the  agency and list their HCT/Ps</td>
    </tr>
    <tr>
      <td>Currently, we are required to be, and are, licensed to operate in New York and  New Jersey, two of the states in which we <font color="blue">currently collect placentas</font> and  <font color="blue">umbilical cord blood</font> for our allogeneic and <font color="blue">private stem cell banking</font>  <font color="blue">businesses</font></td>
    </tr>
    <tr>
      <td>If other states adopt similar licensing <font color="blue"><font color="blue">requirement</font>s</font>, we would need  to obtain such licenses to continue operating</td>
    </tr>
    <tr>
      <td>If we are delayed in receiving,  or are unable to obtain at all, <font color="blue">necessary</font> licenses, we will be unable to provide  services in those states and this <font color="blue">would impact negatively on</font> our revenues</td>
    </tr>
    <tr>
      <td>WE MAY NOT BE ABLE TO PROTECT OUR INTELLECTUAL PROPERTY AND OUR PRODUCTS MAY BE  SUBJECT TO GENERIC COMPETITION    Our <font color="blue">success depends</font>, in part, on our ability to obtain and <font color="blue">enforce patents</font>,  <font color="blue">protect <font color="blue">trade secret</font>s</font>, obtain licenses to <font color="blue">technology</font> owned <font color="blue">by <font color="blue">third parties</font></font> and  to conduct our business <font color="blue">without infringing upon</font> the <font color="blue">proprietary</font> rights of  others</td>
    </tr>
    <tr>
      <td>The <font color="blue">patent positions</font> of <font color="blue">pharmaceutical</font> and <font color="blue">bio<font color="blue">pharmaceutical</font></font> firms,  including ours, can be uncertain and <font color="blue">involve complex legal</font> and factual  questions</td>
    </tr>
    <tr>
      <td>Under the current US patent laws, patent <font color="blue"><font color="blue">application</font>s</font> <font color="blue">in the <font color="blue">United States</font> </font>are  maintained in <font color="blue">secrecy from four</font> to <font color="blue">eighteen months</font>, and <font color="blue">publication</font> of  <font color="blue">discoveries</font> in the scientific and <font color="blue">patent literature often lag behind actual</font>  <font color="blue">discoveries</font></td>
    </tr>
    <tr>
      <td>Thus, we <font color="blue">may discover sometime</font> in the future that we, or the third  <font color="blue">parties from whom</font> we have <font color="blue">licensed patents</font> or patent <font color="blue"><font color="blue">application</font>s</font>, were not the  first to make and/or file the <font color="blue"><font color="blue">inventions</font> covered by</font> the patents and patent  <font color="blue"><font color="blue">application</font>s</font> in which we have or <font color="blue">seek rights</font></td>
    </tr>
    <tr>
      <td>In the event that a third party  has also filed a patent <font color="blue">application</font> for any of the <font color="blue">inventions</font> claimed in our  patents or patent <font color="blue"><font color="blue">application</font>s</font>, or those we have licensed-in, we <font color="blue">could become</font>  involved in an <font color="blue">interference proceeding</font> declared by the US Patent and Trademark  Office to determine priority of invention or an <font color="blue">opposition proceeding</font> in other  <font color="blue">places such as</font> Europe</td>
    </tr>
    <tr>
      <td>Such an interference or opposition could result in the  loss of an issued US or foreign patent, <font color="blue">respectively</font>, or loss of any  <font color="blue">opportunity</font> to secure US <font color="blue">patent protection</font> for that invention</td>
    </tr>
    <tr>
      <td>Even if the  <font color="blue">eventual outcome</font> is favorable to us, such proceedings could result in  substantial cost and delay to us and limit the scope of the claimed subject  matter</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">coverage sought</font> in a patent <font color="blue">application</font> may not be obtained or  may be <font color="blue">significant</font>ly reduced before the patent is issued</td>
    </tr>
    <tr>
      <td>Consequently, if our  pending <font color="blue"><font color="blue">application</font>s</font>, or pending <font color="blue">application</font> that we have licensed-in from third  parties, do not result in the issuance of patents or if any patents that are  issued do not provide <font color="blue">significant</font> <font color="blue">proprietary</font> protection or commercial  advantage, our ability to sustain the <font color="blue">necessary</font> level of <font color="blue"><font color="blue">intellectual</font> property</font>  <font color="blue">rights upon which</font> our <font color="blue">success depends</font> may be restricted</td>
    </tr>
    <tr>
      <td>Moreover, <font color="blue">different</font> countries have <font color="blue">different</font> procedures for obtaining patents,  and <font color="blue">patents issued</font> in <font color="blue">different</font> countries provide <font color="blue">different</font> degrees of  <font color="blue">protection against</font> the use of a <font color="blue">patented invention by others</font></td>
    </tr>
    <tr>
      <td>Therefore, if the  issuance to us or our <font color="blue">licensors</font>, in a <font color="blue">given country</font>, of a <font color="blue">patent covering</font> an  invention is not <font color="blue">followed by</font> the issuance in other countries of <font color="blue">patents covering</font>  the <font color="blue">same invention</font>, or if any judicial <font color="blue">interpretation</font> of the validity,  <font color="blue">enforceability</font> or scope of the claims in a <font color="blue">patent issued</font> in <font color="blue">one country</font> is not  similar to the <font color="blue">interpretation</font> given to the corresponding <font color="blue">patent issued</font> in  another country, our ability to protect our <font color="blue"><font color="blue">intellectual</font> property</font> in other  <font color="blue">countries may</font> be limited</td>
    </tr>
    <tr>
      <td>Furthermore, even if our patents, or those we have licensed-in, are issued, our  <font color="blue"><font color="blue"><font color="blue">competitors</font> may</font> still challenge</font> the scope, validity or <font color="blue">enforceability</font> of such  patents in court, requiring us to engage in complex, lengthy and costly  <font color="blue">litigation</font></td>
    </tr>
    <tr>
      <td>Alternatively, our <font color="blue"><font color="blue">competitors</font> may</font> be able to <font color="blue">design around such</font>  patents and <font color="blue">compete with us using</font> the resulting <font color="blue">alternative</font> <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>If any  of our issued or <font color="blue">licensed patents</font> are infringed, we may not be successful in  enforcing our or our licensorapstas <font color="blue"><font color="blue">intellectual</font> property</font> rights or                                           24  <PAGE>    defending the validity or <font color="blue">enforceability</font> of our <font color="blue">issued patents</font> and <font color="blue">subsequently</font>  not be able to develop or <font color="blue">market applicable product exclusively</font></td>
    </tr>
    <tr>
      <td>FDA <font color="blue">regulatory</font> exclusivity for thalidomide has expired so that <font color="blue">generic drug</font>  companies can file an abbreviated new drug <font color="blue">application</font>, or ANDA, to seek  approval to market thalidomide in the <font color="blue">United States</font></td>
    </tr>
    <tr>
      <td>However, such an ANDA filer  will need to challenge the validity or <font color="blue">enforceability</font> of our <font color="blue">United States</font>  patents relating to our STEPS(R) program or to <font color="blue">demonstrate</font> that they do not  use an infringing risk <font color="blue">management</font> program</td>
    </tr>
    <tr>
      <td>We <font color="blue">cannot <font color="blue">predict whether</font></font> an ANDA  challenge to our patents will be made, nor can we <font color="blue">predict whether</font> our  STEPS(R) patents can be <font color="blue">circumscribed</font> or invalidated or otherwise rendered  unenforceable</td>
    </tr>
    <tr>
      <td>However, if such an ANDA was filed and <font color="blue">approved by</font> the FDA, and  the generic company was successful in <font color="blue">challenging</font> our patents listed in the  <font color="blue">Orange Book </font>for THALOMID(R), the generic company would be permitted to sell a  generic thalidomide product</td>
    </tr>
    <tr>
      <td>Further, we rely upon unpatented <font color="blue">proprietary</font> and <font color="blue">trade secret</font> <font color="blue">technology</font> that we  try to protect, in part, by <font color="blue">confidentiality</font> <font color="blue"><font color="blue">agreement</font>s</font> with our <font color="blue">collaborative</font>  partners, employees, consultants, outside scientific <font color="blue">collaborators</font>, sponsored  <font color="blue">researchers</font> and other advisors</td>
    </tr>
    <tr>
      <td>If these <font color="blue"><font color="blue">agreement</font>s</font> are breached, we may not  have <font color="blue">adequate remedies</font> for any such breach</td>
    </tr>
    <tr>
      <td>Despite <font color="blue">precautions taken by us</font>,  <font color="blue">others may</font> obtain access to or <font color="blue">independently</font> develop our <font color="blue">proprietary</font> <font color="blue">technology</font>  or such <font color="blue">technology</font> may be found to be non-<font color="blue">proprietary</font> or not a <font color="blue">trade secret</font></td>
    </tr>
    <tr>
      <td>Our right to practice the <font color="blue">inventions</font> claimed in <font color="blue">certain patents</font> that relate to  THALOMID(R) arises <font color="blue">under licenses granted</font> to <font color="blue">us by others</font>, including The  Rockefeller University and Childrenapstas Medical Center Corporation, or CMCC In  addition to these patents, which relate to thalidomide, we have <font color="blue">also licensed</font>  from CMCC <font color="blue">certain patents</font> relating to <font color="blue">thalidomide analogs</font></td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2002, we  <font color="blue">entered into</font> an exclusive license <font color="blue"><font color="blue">agreement</font> with</font> CMCC and EntreMed Inc</td>
    </tr>
    <tr>
      <td>pursuant  to which CMCC <font color="blue">exclusively licensed</font> to us <font color="blue">certain patents</font> and patent <font color="blue"><font color="blue">application</font>s</font>  that relate to analogs, metabolites, precursors and <font color="blue">hydrolysis products</font> of  thalidomide, and all <font color="blue">stereoisomers thereof</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">license under</font> the <font color="blue">December </font>2002  <font color="blue">agreement</font> is worldwide and royalty-bearing, and we have complete <font color="blue">control over</font>  the <font color="blue">prosecution</font> of the <font color="blue">licensed thalidomide analog patent rights</font></td>
    </tr>
    <tr>
      <td>Under this  <font color="blue">December </font>2002 <font color="blue">agreement</font>, we are obligated to <font color="blue">comply with</font> certain <font color="blue">milestones</font> for  a REVLIMID(R) approval and <font color="blue">royalties with respect</font> to sales of REVLIMID(R)</td>
    </tr>
    <tr>
      <td>The  <font color="blue">December </font>2002 <font color="blue">agreement</font> also grants us an option for a certain time period to  <font color="blue">inventions</font> in the field of <font color="blue">thalidomide analogs</font> that may be developed at CMCC in  the <font color="blue">laboratory</font> of Dr</td>
    </tr>
    <tr>
      <td><font color="blue">Robert D </font>&amp;apos Amato, pursuant to the terms and <font color="blue">conditions</font> of a  separate <font color="blue">Sponsored Research Agreement </font><font color="blue">negotiated between</font> CMCC and us</td>
    </tr>
    <tr>
      <td>Further, while we believe these <font color="blue">confidentiality</font> <font color="blue"><font color="blue">agreement</font>s</font> and license  <font color="blue"><font color="blue">agreement</font>s</font> to be valid and enforceable, our <font color="blue">rights under</font> these <font color="blue"><font color="blue">agreement</font>s</font> may  not continue or <font color="blue">disputes concerning</font> these <font color="blue"><font color="blue">agreement</font>s</font> may arise</td>
    </tr>
    <tr>
      <td>If any of the  <font color="blue">foregoing should</font> occur, we may be unable to rely upon our unpatented <font color="blue">proprietary</font>  and <font color="blue">trade secret</font> <font color="blue">technology</font>, or we may be unable to use the third-party  <font color="blue">proprietary</font> <font color="blue">technology</font> we have licensed-in, either of <font color="blue">which may prevent</font> or  <font color="blue">hamper us from successfully pursuing</font> our business</td>
    </tr>
    <tr>
      <td>On August 19, 2004, we, together with our <font color="blue">exclusive licensee</font> Novartis, filed an  infringement action <font color="blue">in the <font color="blue">United States</font> </font>District Court of <font color="blue">New Jersey </font>against  Teva Pharmaceuticals USA, Inc, in response to notices <font color="blue">of Paragraph IV  </font><font color="blue">certifications</font> made by Teva in <font color="blue"><font color="blue">connection</font> with</font> the filing <font color="blue">of an ANDA </font>for  FOCALIN(TM)</td>
    </tr>
    <tr>
      <td>The <font color="blue">notification letters contend</font> that <font color="blue">United States</font> Patent Nos</td>
    </tr>
    <tr>
      <td>The  &amp;apos 656  patent is currently the subject of <font color="blue">reexamination proceedings</font> in the United  States Patent and Trademark Office</td>
    </tr>
    <tr>
      <td>After the suit was filed, Novartis listed  another patent, <font color="blue">United States</font> Patent Nodtta 6cmam528cmam530, or  &amp;apos 530 patent, in the  <font color="blue">Orange Book </font>in <font color="blue">association</font> with the FOCALIN(TM) NDA Neither the  &amp;apos 656 patent nor  the  &amp;apos 530 patent is part of the <font color="blue">patent infringement action against</font> Teva</td>
    </tr>
    <tr>
      <td>Recently, Teva amended its answer to contend that the   &amp;apos 850 patent was not                                           25  <PAGE>    <font color="blue">infringed by</font> the filing of its ANDA, and that the  &amp;apos 850 patent is not enforceable  due to an <font color="blue">allegation</font> of <font color="blue">inequitable conduct</font></td>
    </tr>
    <tr>
      <td>Fact <font color="blue">discovery</font> expired on <font color="blue"><font color="blue">February </font> </font>28, 2006</td>
    </tr>
    <tr>
      <td>If successful, Teva will be permitted to  sell a <font color="blue">generic version</font> of FOCALIN(TM), <font color="blue">which could <font color="blue">significant</font>ly</font> reduce our  sales of FOCALIN(TM) to Novartis</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that third-party patent <font color="blue"><font color="blue">application</font>s</font> and patents could issue  with claims that <font color="blue">broadly cover certain aspects</font> of our business or of the subject  matter claimed in the patents or patent <font color="blue"><font color="blue">application</font>s</font> owned or <font color="blue">optioned by us</font> or  licensed to us, which may limit our ability to conduct our business or to  <font color="blue">practice under</font> our patents, and may impede our efforts to obtain <font color="blue">meaningful</font>  <font color="blue">patent protection</font> of our own</td>
    </tr>
    <tr>
      <td>If patents are issued to <font color="blue">third parties</font> that  <font color="blue">contain competitive</font> or <font color="blue">conflicting</font> claims, we may be <font color="blue">legally prohibited from</font>  pursuing research, <font color="blue">development</font> or <font color="blue">commercialization</font> of <font color="blue">potential products</font> or be  required to obtain licenses to these patents or to develop or obtain <font color="blue">alternative</font>  <font color="blue">technology</font></td>
    </tr>
    <tr>
      <td>We may be <font color="blue">legally prohibited from</font> using patented <font color="blue">technology</font>, may not  be able to obtain any license to the patents and <font color="blue">technologies</font> of <font color="blue">third parties</font>  on acceptable terms, if at all, or may not be able to obtain or develop  <font color="blue">alternative</font> <font color="blue">technologies</font></td>
    </tr>
    <tr>
      <td>Consequently, if we cannot successfully <font color="blue">defend against</font>  any <font color="blue">patent infringement suit</font> that may be brought <font color="blue">against us</font> by a third-party, we  may lose the ability to continue to conduct our business as we presently do, or  to <font color="blue">practice certain</font> subject matter <font color="blue">delineated by patent</font> claims that we have  <font color="blue">exclusive rights</font> to, <font color="blue">whether by ownership</font> or by license, and that may have a  material adverse effect on our business</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely upon trademarks</font> and service marks to protect our rights to the  <font color="blue"><font color="blue">intellectual</font> property</font> used in our business</td>
    </tr>
    <tr>
      <td>On October 29, 2003, we filed a  <font color="blue">lawsuit against</font> Centocor, Inc</td>
    </tr>
    <tr>
      <td>to prevent Centocorapstas use of the term  &amp;quote IMIDs &amp;quote   in <font color="blue"><font color="blue">connection</font> with</font> Centocorapstas products, which use, we believe, is likely to  cause <font color="blue">confusion with</font> our IMiDs(R) <font color="blue">registered trademark</font> for compounds (including  REVLIMID(TM)) developed or being developed by us to <font color="blue">treat cancer</font> and  <font color="blue">inflammatory diseases</font></td>
    </tr>
    <tr>
      <td>If we are not successful in this suit, it may be  <font color="blue">necessary</font> for us to adopt a <font color="blue">different</font> trademark for that class of compounds and  thereby lose the value we believe we have built in the  &amp;quote IMiDs(R) &amp;quote  mark</td>
    </tr>
    <tr>
      <td><font color="blue">On January </font>15, 2004, an <font color="blue">opposition proceeding</font> was <font color="blue">brought by</font> Celltech R&amp;D Ltd</td>
    </tr>
    <tr>
      <td><font color="blue">against granted</font> <font color="blue">European Patent </font>0728143 which we have <font color="blue">licensed from</font> the  <font color="blue">University of California </font>relating to JNK 1 and JNK 2 polypeptides</td>
    </tr>
    <tr>
      <td>This  proceeding is <font color="blue">directed solely</font> to our claims for JNK 2 and not JNK 1</td>
    </tr>
    <tr>
      <td>An oral  hearing occurred in October of 2005 in which the <font color="blue">European Patent </font>Office advised  us of its intent to <font color="blue">revoke certain</font> of our claims</td>
    </tr>
    <tr>
      <td>We await a <font color="blue">written decision</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">written decision</font> may be appealed</td>
    </tr>
    <tr>
      <td>We do have other JNK 1 and <font color="blue">JNK European  </font>patent <font color="blue">application</font> claims pending</td>
    </tr>
    <tr>
      <td>THE PHARMACEUTICAL AND BIOTECH INDUSTRY IS HIGHLY COMPETITIVE AND SUBJECT TO  RAPID AND SIGNIFICANT TECHNOLOGICAL CHANGE    The <font color="blue">pharmaceutical</font> industry in which we operate is <font color="blue">highly competitive</font> and  subject to rapid and <font color="blue">significant</font> <font color="blue">technological</font> change</td>
    </tr>
    <tr>
      <td>Our present and potential  <font color="blue">competitors</font> include major <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> companies, as well as  specialty <font color="blue">pharmaceutical</font> firms, including but not limited to:         o    Amgen, <font color="blue"><font color="blue">which potentially compete</font>s</font> with our TNF(alpha) and kinase            <font color="blue">inhibitors</font>;         o    Novartis, <font color="blue"><font color="blue">which potentially compete</font>s</font> with our IMiDs(R) compounds and            <font color="blue">kinase programs</font>;         o    Bristol Myers Squibb Co, <font color="blue"><font color="blue">which potentially compete</font>s</font> in clinical            <font color="blue">trials with</font> our IMiDs(R) compounds and TNF(alpha) <font color="blue">inhibitors</font>;                                           26  <PAGE>         o    Genentech, Inc, <font color="blue"><font color="blue">which potentially compete</font>s</font> in <font color="blue">clinical trials</font> with            our IMiDs(R) compounds and TNF(alpha) <font color="blue">inhibitors</font>;         o    <font color="blue">AstraZeneca </font>plc, <font color="blue"><font color="blue">which potentially compete</font>s</font> in <font color="blue">clinical trials</font> with            our IMiDs(R) compounds and TNF(alpha) <font color="blue">inhibitors</font>;         o    Millennium Pharmaceuticals Inc, <font color="blue"><font color="blue">which potentially compete</font>s</font> in            <font color="blue">clinical trials</font> with our IMiDs(R) <font color="blue">compounds as well as with</font>            THALOMID(R);         o    <font color="blue">Vertex Pharmaceuticals Inc</font></td>
    </tr>
    <tr>
      <td>and Pfizer Inc, <font color="blue">which potentially compete</font>            in <font color="blue">clinical trials</font> with our kinase <font color="blue">inhibitors</font>; and         o    <font color="blue">Biogen IDEC Inc</font></td>
    </tr>
    <tr>
      <td>and Genzyme Corporation, both of which are <font color="blue">generally</font>            developing drugs that address the oncology and <font color="blue">immunology markets</font></td>
    </tr>
    <tr>
      <td>Many of these companies have <font color="blue">considerably</font> greater financial, technical and  marketing resources than we</td>
    </tr>
    <tr>
      <td>We also experience <font color="blue"><font color="blue">competition</font> from universities</font>  and other <font color="blue">research institutions</font>, and in some instances, we <font color="blue">compete with others</font>  in acquiring <font color="blue">technology</font> from these sources</td>
    </tr>
    <tr>
      <td>The <font color="blue">pharmaceutical</font> industry has  undergone, and is expected to continue to undergo, rapid and <font color="blue">significant</font>  <font color="blue">technological</font> change, and we expect <font color="blue">competition</font> to <font color="blue">intensify as technical</font>  advances in the field are made and become more <font color="blue">widely known</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of  products or <font color="blue">processes by</font> our <font color="blue">competitors</font> with <font color="blue">significant</font> <font color="blue">advantages</font> over those  that we are seeking to develop could cause the <font color="blue">marketability</font> of our products to  stagnate or decline</td>
    </tr>
    <tr>
      <td>SALES OF OUR PRODUCTS ARE DEPENDENT ON THIRD-PARTY REIMBURSEMENT    Sales of our <font color="blue">products will</font> depend, in part, on the extent to which the costs of  our <font color="blue">products will</font> be paid by health maintenance, managed care, pharmacy benefit  and similar health care <font color="blue">management</font> organizations, or reimbursed by <font color="blue">government</font>  health <font color="blue">administration</font> <font color="blue">authorities</font>, private health coverage insurers and other  third-party payors</td>
    </tr>
    <tr>
      <td>These health care <font color="blue">management</font> organizations and third-party  payors are increasingly <font color="blue">challenging</font> the <font color="blue">prices charged</font> for <font color="blue">medical products</font> and  services</td>
    </tr>
    <tr>
      <td>Additionally, the <font color="blue">containment</font> of health care costs has become a  priority of federal and state <font color="blue">government</font>s, and the prices of drugs have been a  focus in this effort</td>
    </tr>
    <tr>
      <td>If these organizations and third-party payors do not  consider our products to be cost-<font color="blue">effective</font> or <font color="blue">competitive with</font> other available  therapies, they may not <font color="blue">reimburse providers</font> or consumers of our products or, if  they do, the level of <font color="blue">reimbursement</font> may not be sufficient to allow us to sell  our <font color="blue">products on</font> a <font color="blue">profitable basis</font></td>
    </tr>
    <tr>
      <td>WE HAVE GROWN RAPIDLY, AND IF WE FAIL TO ADEQUATELY MANAGE THAT GROWTH OUR  BUSINESS COULD BE ADVERSELY IMPACTED    We have an <font color="blue">aggressive growth</font> plan that has included substantial and increasing  <font color="blue">investments</font> in research and <font color="blue">development</font>, sales and marketing, and <font color="blue">facilities</font></td>
    </tr>
    <tr>
      <td>We  plan to continue to grow and our plan has a number of risks, some of which we  <font color="blue">cannot control</font></td>
    </tr>
    <tr>
      <td>For example:         o    we will need to <font color="blue">generate higher revenues</font> to cover a <font color="blue">higher level</font> of            operating expenses, and our ability to do so <font color="blue">may depend on factors</font>            that we do not control;         o    we will need to <font color="blue">assimilate new staff members</font>;         o    we will need to manage complexities <font color="blue">associated with</font> a larger and            <font color="blue">faster growing multinational organization</font>; and                                           27  <PAGE>         o   we will need to <font color="blue">accurately</font> anticipate demand for the products we           <font color="blue">manufacture</font> and maintain adequate <font color="blue">manufacturing</font> capacity, and our           ability to do so <font color="blue">may depend on factors</font> that we do not control</td>
    </tr>
    <tr>
      <td>THE PRICE OF OUR COMMON STOCK MAY FLUCTUATE SIGNIFICANTLY, WHICH MAY MAKE IT  DIFFICULT FOR YOU TO SELL THE COMMON STOCK WHEN YOU WANT OR AT PRICES YOU FIND  ATTRACTIVE    There has been <font color="blue">significant</font> <font color="blue">volatility</font> in the <font color="blue"><font color="blue">market price</font>s</font> for <font color="blue">publicly traded</font>  shares of <font color="blue">bio<font color="blue">pharmaceutical</font></font> companies, including ours</td>
    </tr>
    <tr>
      <td>We expect that the market  price of our <font color="blue">common stock</font> will continue to fluctuate</td>
    </tr>
    <tr>
      <td>After <font color="blue">adjusting prices</font> to  reflect our two-for-one <font color="blue">stock split</font> effected on <font color="blue">February </font>17, 2006, the intra-day  price of our <font color="blue">common stock</font> fluctuated from a high of dlra32dtta68 per share to a low of  dlra12dtta35 per share in 2005</td>
    </tr>
    <tr>
      <td>On <font color="blue">December </font>31, 2005, our <font color="blue">common stock</font> closed at a  split-adjusted price of dlra32dtta40 per share</td>
    </tr>
    <tr>
      <td>The price of our <font color="blue">common stock</font> may not  <font color="blue">remain at</font> or <font color="blue">exceed current levels</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">following key factors may</font> have an  <font color="blue">adverse impact on</font> the <font color="blue">market price</font> of our <font color="blue">common stock</font>:         o    results of our <font color="blue">clinical trials</font> or adverse events <font color="blue">associated with</font> our            <font color="blue">marketed products</font>;         o    <font color="blue">announcements</font> of technical or product <font color="blue">development</font>s by our <font color="blue">competitors</font>;         o    market <font color="blue">conditions</font> for <font color="blue">pharmaceutical</font> and bio<font color="blue">technology</font> stocks;         o    market <font color="blue">conditions</font> <font color="blue">generally</font>;         o    <font color="blue">government</font>al regulation;         o    health care <font color="blue">legislation</font>;         o    public <font color="blue">announcements</font> regarding <font color="blue">medical advances</font> in the treatment of            the disease states that we are targeting;         o    patent or <font color="blue">proprietary</font> rights <font color="blue">development</font>s;         o    changes in pricing and third-party <font color="blue"><font color="blue">reimbursement</font> policies</font> for our            products; or         o    <font color="blue">fluctuations</font> in our operating results</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">stock market</font> in general and the bio<font color="blue">technology</font> sector in  particular has experienced extreme <font color="blue">volatility</font> that has often been unrelated to  the operating performance of a <font color="blue">particular company</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">broad market</font>  <font color="blue">fluctuations</font> may adversely affect the <font color="blue">market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>THE NUMBER OF SHARES OF OUR COMMON STOCK ELIGIBLE FOR FUTURE SALE COULD  ADVERSELY AFFECT THE MARKET PRICE OF OUR COMMON STOCK    Future sales of substantial amounts of our <font color="blue">common stock</font> or debt or other  securities convertible into <font color="blue">common stock</font> could adversely affect the <font color="blue">market price</font>  of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, after <font color="blue">adjusting prices</font> to reflect  our two-for-one <font color="blue">stock split</font> effected on <font color="blue">February </font>17, 2006, there were  outstanding <font color="blue">stock options</font> and warrants for 50cmam999cmam074 shares of <font color="blue">common stock</font>, of  which 49cmam865cmam160 were <font color="blue">currently exercisable at</font> an <font color="blue"><font color="blue">exercise price</font> range between</font>  dlra0dtta04 per share and dlra35dtta67 per share, with a <font color="blue">weighted average <font color="blue">exercise price</font></font> of  dlra13dtta95 per share</td>
    </tr>
    <tr>
      <td>In addition, in June 2003, we issued dlra400dtta0 million                                           28  <PAGE>    of unsecured convertible notes that are currently convertible into 33cmam022cmam360  shares of our <font color="blue">common stock</font> at the <font color="blue">conversion</font> price of dlra12dtta1125</td>
    </tr>
    <tr>
      <td>The <font color="blue">conversion</font>  of some or all of these notes <font color="blue">will dilute</font> the <font color="blue">ownership interest</font> of existing  <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>OUR SHAREHOLDER RIGHTS PLAN AND CERTAIN CHARTER AND BY-LAW PROVISIONS MAY DETER  A THIRD-PARTY FROM ACQUIRING US AND MAY IMPEDE THE STOCKHOLDERS &amp;apos  ABILITY TO  REMOVE AND REPLACE OUR MANAGEMENT OR BOARD OF DIRECTORS    Our board of <font color="blue">directors</font> has adopted a <font color="blue">shareholder rights</font> plan, the purpose of  which is to protect <font color="blue">stockholders</font> against unsolicited attempts to acquire control  of us that do not offer a fair price to all of our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights plan  may have the effect of dissuading a <font color="blue">potential acquirer from</font> making an offer for  our <font color="blue">common stock</font> at a price that <font color="blue">represents</font> a premium to the <font color="blue">then current</font>  <font color="blue">trading price</font></td>
    </tr>
    <tr>
      <td>Our board of <font color="blue">directors</font> has the authority to issue, at any time, <font color="blue">without further</font>  stockholder approval, up to 5cmam000cmam000 shares of <font color="blue">preferred stock</font>, and to  determine the price, rights, privileges and <font color="blue">preferences</font> of those shares</td>
    </tr>
    <tr>
      <td>An  issuance of <font color="blue">preferred stock</font> could discourage a third-party from acquiring a  majority of our <font color="blue">outstanding voting stock</font></td>
    </tr>
    <tr>
      <td>Additionally, our board of <font color="blue">directors</font>  has <font color="blue">adopted certain <font color="blue">amendments</font></font> to our by-laws intended to strengthen the boardapstas  position in the event of a <font color="blue">hostile takeover attempt</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">provisions could</font>  impede the <font color="blue">stockholders</font> &amp;apos  ability to remove and replace our <font color="blue">management</font> and/or  board of <font color="blue">directors</font></td>
    </tr>
    <tr>
      <td>Furthermore, we are subject to the provisions of Section 203 of the Delaware  General Corporation Law, an anti-takeover law, which may also dissuade a  potential acquirer of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td><font color="blue">BEGINNING IN JANUARY </font>2006, WE WILL BE REQUIRED TO EXPENSE THE FAIR VALUE OF  STOCK OPTIONS GRANTED UNDER OUR STOCK INCENTIVE PLANS AND OUR NET INCOME AND  EARNINGS PER SHARE WILL BE SIGNIFICANTLY REDUCED AS A RESULT    In <font color="blue">December </font>2004, the Financial Accounting Standards Board, or FASB, issued  Statement of Financial Accounting Standards Nodtta 123R,  &amp;quote Share-Based Payment, &amp;quote  or  SFAS 123R SFAS 123R requires <font color="blue"><font color="blue">compensation</font> cost</font> relating to share-based payment  <font color="blue">transaction</font>s be recognized in <font color="blue">financial statements</font> <font color="blue">based on</font> the <font color="blue">fair value</font> of  the equity or <font color="blue">liability instruments issued</font></td>
    </tr>
    <tr>
      <td>SFAS 123R covers a wide range of  share-based <font color="blue">compensation</font> <font color="blue">arrangements</font> including <font color="blue">stock options</font>, restricted stock  plans, performance-based awards, stock appreciation rights, and <font color="blue">employee stock</font>  purchase plans</td>
    </tr>
    <tr>
      <td>SFAS Nodtta 123, as originally issued in 1995, established as  preferable a fair-value-based method of <font color="blue">accounting</font> for share-based payment  <font color="blue">transaction</font>s with employees</td>
    </tr>
    <tr>
      <td>However, SFAS Nodtta 123 permitted entities to  continue to apply the guidance in APB Opinion Nodtta 25, as long as the footnotes  to <font color="blue">financial statements</font> disclosed what <font color="blue">net income would</font> have been had the  preferable fair-value-based method been used</td>
    </tr>
    <tr>
      <td>We will be required to adopt the  provisions of SFAS Nodtta 123R in the <font color="blue">first quarter</font> of fiscal year 2006</td>
    </tr>
    <tr>
      <td><font color="blue"><font color="blue">Management </font> </font>is <font color="blue">currently evaluating</font> the <font color="blue"><font color="blue">requirement</font>s</font> of SFAS Nodtta 123R The adoption of SFAS  Nodtta 123R is expected to have a material effect on our <font color="blue">consolidated financial</font>  statements</td>
    </tr>
    <tr>
      <td>See Note 1, Nature of Business and Summary of Significant Accounting  Policies, to the Consolidated Financial Statements included elsewhere in this  <font color="blue">Annual Report </font>for the <font color="blue">pro forma impact on net income</font> and <font color="blue">net income per</font> share  from calculating stock-based <font color="blue"><font color="blue">compensation</font> cost</font> under the <font color="blue">fair value</font> method of  SFAS Nodtta 123</td>
    </tr>
    <tr>
      <td>However, the <font color="blue">calculation</font> of <font color="blue"><font color="blue">compensation</font> cost</font> for share-based  payment <font color="blue">transaction</font>s after the <font color="blue">effective</font> date of SFAS Nodtta 123R may be <font color="blue">different</font>  from the <font color="blue">calculation</font> of <font color="blue"><font color="blue">compensation</font> cost</font> under SFAS Nodtta 123</td>
    </tr>
    <tr>
      <td>In <font color="blue">December </font>2005, in <font color="blue">recognition</font> of the significance of the REVLIMID(R)  <font color="blue">regulatory</font> approval, the <font color="blue">Board of Directors </font>approved a resolution to grant the  2006 annual stock option awards in 2005 pursuant to the 1998 Stock Incentive  Plan, or the 1998 Plan, and the 1998 Non-Employee Directors &amp;apos  <font color="blue">Incentive Plan</font></td>
    </tr>
    <tr>
      <td>All  <font color="blue">stock options</font> awarded pursuant to the 1998 Plan were granted fully vested, with  <font color="blue">half issued at</font> an <font color="blue">exercise price</font>, or <font color="blue">strike price</font>, of dlra34dtta05 per option and the  other <font color="blue">half issued at</font> a <font color="blue">strike price</font> of dlra35dtta67 per option, which was at a premium  to the closing price of dlra32dtta43, adjusted for the <font color="blue">February </font>17, 2006 two-for-one  <font color="blue">stock split</font>, of our <font color="blue">common stock</font> on the <font color="blue">Nasdaq National Market </font>on the grant date  of <font color="blue">December </font>29, 2005</td>
    </tr>
    <tr>
      <td>The Boardapstas decision to grant these options was in  <font color="blue">recognition</font> of the REVLIMID(R) <font color="blue">regulatory</font> approval and in response to a review  of our long-term incentive <font color="blue">compensation</font> programs in light of changes in market  practices and <font color="blue">recently issued</font> changes in <font color="blue">accounting</font> rules resulting from the  issuance of FASB Nodtta 123R, which we are required to adopt <font color="blue">effective</font> the first  quarter of 2006</td>
    </tr>
    <tr>
      <td><font color="blue">Management </font>believes that granting these <font color="blue">options prior</font> to the  adoption of FASB Nodtta 123R will result in our not being required to recognize  cumulative <font color="blue">compensation</font> expense of approximately dlra70dtta8 million for the four-year  period ending <font color="blue">December </font>31, 2009</td>
    </tr>
    <tr>
      <td>AVAILABLE INFORMATION    Our current reports on Form 8-K, quarterly reports on Form 10-Q and annual  reports on Form 10-K are <font color="blue">electronically filed with</font> or furnished to the  Securities and Exchange Commission, or SEC, and all such reports and <font color="blue">amendments</font>  to such reports filed have been and will be made available, free of charge,  through our website (http://www</td>
    </tr>
    <tr>
      <td>com) as soon as reasonably practicable  after such filing</td>
    </tr>
    <tr>
      <td>Such reports <font color="blue">will remain available on</font> our website for at  <font color="blue">least twelve months</font></td>
    </tr>
    <tr>
      <td>The contents of our website are not <font color="blue">incorporated by</font>  <font color="blue">reference into</font> this annual report</td>
    </tr>
    <tr>
      <td>The <font color="blue">public may</font> read and copy any materials  <font color="blue">filed by us with</font> the SEC at the SECapstas Public Reference Room at 100 F Street, NW,  Washington, DC 20549</td>
    </tr>
    <tr>
      <td>The <font color="blue">public may</font> obtain information on the operation of the <font color="blue">Public Reference Room  </font>by calling the SEC at 1-800-SEC-0330</td>
    </tr>
    <tr>
      <td>gov) that contains reports, proxy and information statements,  and other information regarding issuers that <font color="blue">file electronically with</font> the SEC</td>
    </tr>
  </tbody>
</table>